Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
Shere-Wolfe
K D
KD
Verley
J R
JR
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D003402:Creatine Kinase / Q000378:metabolism*; D015658:HIV Infections / Q000188:drug therapy / Q000201:enzymology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D000068698:Tenofovir; D003402:Creatine Kinase; D000225:Adenine